PROBLEM TO BE SOLVED: To provide a new compound which activates Wnt/p-catenin signaling and thus treats or prevents: diseases related to signal transduction, such as osteoporosis and osteoarthropathy, osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, and oncolytic bone disease； traumatic brain injuries related to the differentiation and development of the central nervous system, comprising Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, and schizophrenia； eye diseases such as age related macular degeneration, diabetic macular edema and retinitis pigmentosa； and diseases related to differentiation and growth of stem cell, comprising hair loss, hematopoiesis related diseases and tissue regeneration related diseases.SOLUTION: The present invention relates to β-diketone, γ-diketone or γ-hydroxyketone or analogs thereof which is a compound having a structure of formula I or pharmaceutically acceptable salts or prodrugs thereof.SELECTED DRAWING: None【課題】Wnt/p-カテニンシグナル伝達を活性化し、従って、シグナル伝達に関連する疾患、例えば、骨粗鬆症及び骨関節症、骨形成不全症、骨欠損、骨折、歯周病、耳硬化症、創傷治癒、頭蓋顔面欠損、腫瘍崩壊性骨疾患；パーキンソン病、脳卒中、虚血性脳疾患、てんかん、アルツハイマー病、うつ病、双極性障害、統合失調症を含む、中枢神経系の分化及び発生に関連する外傷性脳損傷；加齢黄斑変性、糖尿病黄斑浮腫又は網膜色素変性症などの眼疾患；並びに脱毛、造血関連疾患及び組織再生関連疾患を含む、幹細胞の分化及び増殖に関連する疾患を処置又は予防する新規化合物の提供。【解決手段】式Ｉの構造を有する化合物又は薬学的に許容されるその塩若しくはプロドラッグである、β-ジケトン、γ-ジケン若しくはγ-ヒドロキシケトン、又はそれらの類似体。【選択図】なし
